<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Screening for melanoma in adults and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Screening for melanoma in adults and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Screening for melanoma in adults and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan C Geller, RN, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan Swetter, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joann G Elmore, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hensin Tsao, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The incidence of melanoma skin cancer, the most fatal form of skin cancer, is increasing faster than any other potentially preventable cancer in the United States [<a href="#rid1">1</a>].</p><p>Screening for melanoma refers to the routine examination of asymptomatic individuals to identify suspicious lesions that require evaluation to establish a diagnosis. This topic discusses screening for melanoma with a skin examination, either during a clinical examination by a primary care clinician or by patient self-examination.</p><p>Specifics about clinical features and diagnosis of melanoma, risk factors for melanoma, inherited susceptibility to melanoma, primary prevention of melanoma, melanoma in children, and staging of melanoma are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4844.html" rel="external">"Melanoma: Epidemiology and risk factors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7624.html" rel="external">"Inherited susceptibility to melanoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4842.html" rel="external">"Primary prevention of melanoma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/101324.html" rel="external">"Melanoma in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7618.html" rel="external">"Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma"</a>.)</p><p></p><p>Skin examination can also detect skin cancers that have a more favorable prognosis than melanoma, including basal cell and squamous cell carcinomas that require excision. Treatment of these are discussed separately. (See  <a class="medical medical_review" href="/d/html/5338.html" rel="external">"Treatment and prognosis of basal cell carcinoma at low risk of recurrence"</a> and  <a class="medical medical_review" href="/d/html/5339.html" rel="external">"Treatment and prognosis of low-risk cutaneous squamous cell carcinoma (cSCC)"</a>.)</p><p class="headingAnchor" id="H18038394"><span class="h1">EPIDEMIOLOGY AND CLASSIFICATION</span><span class="headingEndMark"> — </span>The age-standardized annual incidence of melanoma worldwide is estimated at 22 in 100,000 people and has been increasing in the past decades [<a href="#rid2">2-4</a>]. However, it is not clear to what extent this represents an increase in true disease occurrence, or an increase in thin melanoma diagnosis due to greater screening or change in biopsy rates or histopathologic diagnosis [<a href="#rid5">5</a>].</p><p>Most melanomas arise as superficial indolent tumors that are confined to the epidermis, where they remain for several years. During this stage, the horizontal or "radial" growth phase, the melanoma is almost always curable by surgical excision alone. Melanomas that infiltrate deep into the dermis are in a "vertical" growth phase and have metastatic potential. A definitive diagnosis of melanoma is made by pathological analysis of a biopsy of the lesion. (See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'Diagnosis confirmation'</a> and  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma", section on 'Growth phases of melanoma'</a>.)</p><p>Melanomas occur in sun-exposed and in non-sun-exposed areas. Non-sun-exposed melanomas are less readily detectable and less responsive to available treatments due to differences in tumor biology between those in non-sun-exposed and sun-exposed areas. Sun exposure is less of a risk factor among darker-skinned persons [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'KIT mutations (acral and mucosal melanoma)'</a>.)</p><p>Melanoma that is confined to the epidermis (eg, melanoma in situ) is generally cured following surgery or other types of treatment. For people with invasive melanoma, five-year survival rates average over 90 percent. Survival rates depend on the stage of the disease at the time of diagnosis, and survival declines steadily as tumor thickness and disease stage increase. (See  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma", section on 'Melanoma in situ'</a> and  <a class="medical medical_review" href="/d/html/7618.html" rel="external">"Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma", section on 'Eighth edition AJCC TNM staging'</a> and  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma"</a>.)</p><p>The four major subtypes of invasive cutaneous melanoma (ie, superficial spreading, lentigo maligna, acral lentiginous, and nodular melanoma) are described elsewhere  (<a class="graphic graphic_table graphicRef57168" href="/d/graphic/57168.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma"</a>.)</p><p class="headingAnchor" id="H1245218964"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Risk factors for melanoma incidence include genetic, phenotypic, and environmental factors  (<a class="graphic graphic_table graphicRef105397" href="/d/graphic/105397.html" rel="external">table 2</a>) and are discussed in detail elsewhere (see  <a class="medical medical_review" href="/d/html/4844.html" rel="external">"Melanoma: Epidemiology and risk factors"</a>).</p><p>In addition, there are also certain characteristics that place patients at higher risk of dying from melanoma:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin of color</strong> – Although there is a far lower incidence of melanoma among Black patients, the five-year relative survival is lower than for White patients (69 versus 93 percent) [<a href="#rid7">7,8</a>]. The same trends have been observed in the Hispanic American population, who have a low incidence of melanoma but demonstrate a growing burden of disease and greater likelihood of presenting with advanced disease compared with non-Hispanic White individuals [<a href="#rid9">9,10</a>].</p><p></p><p class="bulletIndent1">Greater mortality in patients with skin of color (eg, skin phototypes IV to VI)  (<a class="graphic graphic_table graphicRef60541" href="/d/graphic/60541.html" rel="external">table 3</a>)<em> </em>may be due to delayed diagnosis due to a lower perceived risk of disease or lower rates of skin examinations, locations of melanoma in atypical non-sun-exposed areas (eg, leg, hip, and feet), a higher proportion of acral and nodular subtypes, and a decreased ability to seek care for localized disease [<a href="#rid11">11-14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>White males over age 50</strong> – Nearly 50 percent of melanoma deaths in the United States occur among White men over age 50, and men in this age group have been found to have a higher risk of death due to melanoma than women in the United States, New Zealand, Australia, and the United Kingdom (particularly West Scotland) [<a href="#rid3">3,15</a>]. Poorer melanoma survival for men may be explained both by differences in tumor biology and by differences in skin awareness, self-examination, and other early detection practices [<a href="#rid16">16-21</a>].</p><p></p><p class="headingAnchor" id="H3310269062"><span class="h1">APPROACH TO SCREENING</span></p><p class="headingAnchor" id="H2192181987"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Not all organizations recommend skin cancer screening. The US Preventive Services Task Force (USPSTF) states that there is inadequate information to make a recommendation for or against population-based screening [<a href="#rid22">22</a>], while other groups such as the Australian Cancer Network and the Canadian Cancer Society suggest screening in high-risk populations [<a href="#rid23">23,24</a>]. Mass skin cancer screening of the entire population is unlikely to be beneficial, feasible, and/or cost-effective.</p><p>We suggest targeted screening of higher-risk groups, along with focused patient and provider education on acral/mucosal melanoma risk and warning signs in people of color. Our approach places a high value on melanoma detection among high-risk patients in the primary care setting.</p><p>We do not use risk assessment tools to determine which patients need screening as these have limited applicability and may be more complex than asking the patient directly about risk factors [<a href="#rid15">15-20</a>].</p><p>If a skin lesion is found, the clinician should make appropriate referrals (to dermatology where possible) for further evaluation of all lesions with prominent features of the ABCDE rule (<strong>a</strong>symmetry, <strong>b</strong>order irregularity, <strong>c</strong>olor variegation, <strong>d</strong>iameter &gt;6 mm, <strong>e</strong>volution), the “ugly duckling” sign (a pigmented lesion that is visibly different from the others in a given individual), the Glasgow seven-point checklist, or other concerning signs or symptoms (eg, itching, bleeding, a lesion growing under a nail or as a pigmented line in a nail) [<a href="#rid25">25</a>]. These clinical prediction rules are discussed in further detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'Indications for referral'</a> and  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'Clinical prediction rules'</a>.)</p><p>Surveillance of patients in melanoma-prone kindreds is described separately. (See  <a class="medical medical_review" href="/d/html/7624.html" rel="external">"Inherited susceptibility to melanoma", section on 'Surveillance in melanoma-prone kindreds'</a>.)</p><p>Genetic testing may be useful to detect increased risk for melanoma only in very limited situations, generally for patients with multiple family members with melanoma. This is described separately. (See  <a class="medical medical_review" href="/d/html/7624.html" rel="external">"Inherited susceptibility to melanoma"</a>.)</p><p class="headingAnchor" id="H3494206081"><span class="h2">High-risk patients</span><span class="headingEndMark"> — </span>For patients at high risk for either developing melanoma, or for mortality due to melanoma, we suggest annual screening with a full-body skin examination by a clinician with skin expertise. The screening examination can take place either during a routine health maintenance visit or another encounter. These patients include those with any of the following characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>White adults age 50 and above.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Total nevus count above 50 and/or presence of large (atypical/dysplastic) nevi. (See  <a class="medical medical_review" href="/d/html/4844.html" rel="external">"Melanoma: Epidemiology and risk factors", section on 'Number of nevi'</a> and  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'History and risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Personal history of skin cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppression, particularly chronic use of medications that suppress the immune system such as that used by organ transplant recipients. (See  <a class="medical medical_review" href="/d/html/16332.html" rel="external">"Epidemiology and risk factors for skin cancer in solid organ transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very sun-sensitive individuals and those with “red hair phenotype” (eg, light skin pigmentation, red or blond hair color, high-density freckling, and light eye color [green, hazel, blue]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A family history of melanoma in one or more first-degree relatives or in more than one second-degree relative on the same side of the lineage. Those with at least three affected members (including one or more first-degree relatives) on one side of the family are at very high risk.</p><p></p><p class="headingAnchor" id="H3826221318"><span class="h2">Non-high-risk patients</span><span class="headingEndMark"> — </span>We suggest not providing routine screening with full-body clinical skin examination in non-high-risk patients. This advice is in keeping with other expert groups including the USPSTF, the Australian Cancer Network, and the Cancer Council Australia [<a href="#rid22">22,23,26</a>].</p><p>However, we do suggest the clinician carefully observe the skin of all patients undergoing a physical examination in the course of a routine or sick visit (opportunistic case finding), particularly in those areas of the skin that are hard for patients themselves to see. A focused skin examination of the palms, soles, and digits may be of value in people with darker skin, who are more likely to have acral melanoma (rather than ultraviolet radiation-related melanoma).</p><p class="headingAnchor" id="H816463966"><span class="h2">Advice to patients</span><span class="headingEndMark"> — </span>We educate all patients about melanoma risk factors and appearance. We advise them to look at and be familiar with their skin and to alert their clinicians if they note changing moles or other suspicious skin lesions. People with darker skin should be educated about examination of the soles/palms/digits.(See <a class="local">'Patient self-examination'</a> below.)</p><p>If a partner, family member, or friend is assisting the patient in examining the skin, it is helpful to have that individual be familiar with the patient’s existing moles so they can identify the ones that change, particularly in hard-to-see areas. Photographs can be helpful for this. (See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'Support techniques for clinical diagnosis'</a>.)</p><p>All patients should be educated about the importance of sun protection for melanoma prevention. (See  <a class="medical medical_review" href="/d/html/4842.html" rel="external">"Primary prevention of melanoma", section on 'Sun protection'</a>.)</p><p class="headingAnchor" id="H1448197031"><span class="h1">PERFORMING SKIN EXAMINATION</span><span class="headingEndMark"> — </span>Methods to screen for melanoma involve visual examination of the skin. Both clinicians and patients should have a systematic approach and need to know what to look for in order to perform an effective total body skin examination.</p><p class="headingAnchor" id="H1530613701"><span class="h2">Clinician total body skin examination</span><span class="headingEndMark"> — </span>The clinician performing a total body skin examination should standardize the order in which the examination is performed, both to ensure completeness and because the clinician examination serves as a model for patient skin self-examination. Thus, if a clinician ignores an area, it may convey the unintended message to the patient that this area is unimportant and that they can ignore it as well.</p><p>Melanomas can occur anywhere on the skin surface. Screening the total skin surface, including the scalp and soles of the feet, all of which are harder to view with self-examination, could aid early detection. Relative to their incidence, scalp lesions have greater mortality, and this area should be examined carefully by clinicians. Men have more lesions of the back whereas women have more lesions on their lower legs, since these are common areas for sunburn and sun exposure [<a href="#rid27">27</a>]. (See <a class="local">'Effectiveness of screening'</a> below.)</p><p>Clinician examination for skin cancer can be carried out in a few minutes, with the following tools and technique:</p><p class="bulletIndent1"><span class="glyph">●</span>Tools</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Source of bright light</p><p class="bulletIndent2"><span class="glyph">•</span>Magnifying lens</p><p class="bulletIndent2"><span class="glyph">•</span>For health providers trained in its use, a dermatoscope (see  <a class="medical medical_review" href="/d/html/13521.html" rel="external">"Overview of dermoscopy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perform the skin examination in a systematic order</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Seated examination of:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Face, head and neck</p><p class="bulletIndent3"><span class="glyph">-</span>Scalp (part the hair or use a blow dryer)</p><p class="bulletIndent3"><span class="glyph">-</span>All surfaces of arms and hands</p><p class="bulletIndent3"><span class="glyph">-</span>Axilla</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Seated or standing examination of the posterior aspect of the upper body</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Supine examination of the chest, abdomen, anterior thighs and legs, dorsal feet, soles, and toe webs</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prone examination of the calves, posterior thighs, buttocks, and back</p><p></p><p class="headingAnchor" id="H4099425328"><span class="h2">Patient self-examination</span><span class="headingEndMark"> — </span>In self-examination, particular attention must be devoted to screening of the back, particularly for men, because approximately one-half of melanomas occur on the trunk on men [<a href="#rid28">28-30</a>] and approximately one-third on the back [<a href="#rid31">31</a>]. It is difficult to perform self-examination of the back, so partners, friends, or family may need to participate in the examination. If patients cannot examine their back or do not have someone else to do this, they should be requesting such examinations from their clinician.</p><p>Having a partner involved in skin self-examination may increase the rates of self-examination performance and melanoma detection. It is helpful to have that individual know the patient’s moles as well so they can identify the ones that change, particularly in hard-to-see areas. Patients and/or partners can also take photographs of suspect moles [<a href="#rid32">32</a>]. Patients who detect a suspect skin lesion should contact their clinicians promptly for further evaluation.</p><p class="bulletIndent1"><span class="glyph">●</span>Tools</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Full-length mirror</p><p class="bulletIndent2"><span class="glyph">•</span>Hand mirror (for closer inspection of the back of the neck, scalp, back, and buttocks)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perform the skin examination in systematic order</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Entire front and back of the body</p><p class="bulletIndent2"><span class="glyph">•</span>Sides of the body with arms raised</p><p class="bulletIndent2"><span class="glyph">•</span>Palms, forearms, upper arms, and axillae</p><p class="bulletIndent2"><span class="glyph">•</span>Back of the legs and feet, toe web spaces, and soles of feet</p><p></p><p class="headingAnchor" id="H3110996189"><span class="h2">Recognizing melanoma</span><span class="headingEndMark"> — </span>Certain tools can help clinicians and patients identify lesions to evaluate further for melanoma. These include the "ugly duckling" sign, the ABCDE rule of melanoma  (<a class="graphic graphic_picture graphicRef52518" href="/d/graphic/52518.html" rel="external">picture 1</a>), and the Glasgow revised seven-point checklist. However, melanomas in prepubertal and pubertal children often lack the conventional ABCDE criteria and may be clinically amelanotic (nonpigmented). The clinical features of melanoma are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'Clinical prediction rules'</a>.)</p><p>Detecting melanoma in children is discussed separately. (See  <a class="medical medical_review" href="/d/html/101324.html" rel="external">"Melanoma in children", section on 'Physical examination'</a>.)</p><p>Examples of typical melanomas are shown in photographs  (<a class="graphic graphic_picture graphicRef74278 graphicRef61158 graphicRef71893 graphicRef64980 graphicRef51085 graphicRef63894 graphicRef80955 graphicRef62791 graphicRef51998" href="/d/graphic/74278.html" rel="external">picture 2A-I</a>). Further photographs are provided elsewhere. (See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H335352545"><span class="h1">RATIONALE FOR SCREENING</span><span class="headingEndMark"> — </span>The benefits of screening for melanoma may seem straightforward because the prognosis of melanoma is significantly better for early-stage (thinner) melanoma which is curable by simple excision compared with later-stage melanoma. In addition, visual skin examination is safe and well tolerated by patients, and risk factors for melanoma are readily identifiable [<a href="#rid33">33,34</a>].</p><p>However the harms of screening for melanoma include the potential that false-positive findings on skin examination will lead to an increased number of dermatology referrals and unnecessary biopsies, and the possibility of overdiagnosis (ie, the diagnosis of melanoma that is either biologically indolent or so slow-growing that it would never become clinically meaningful during the patient’s lifetime). (See <a class="local">'Harms of screening'</a> below.)</p><p>Further, the effectiveness of a screening skin examination depends on several factors including the clinician’s ability to identify early-stage disease, the natural history of melanomas subtypes, the pathologist’s ability to diagnose and histologically stage the disease, and identification of the tumor at a stage where treatment would be more effective.</p><p>The effectiveness of screening is also influenced by the fact that not all subtypes of melanoma have biologic and clinical factors that are conducive to recognition by visual examination, particularly the nodular melanoma subtype, which may be clinically amelanotic [<a href="#rid35">35-38</a>]. In addition, some melanomas may be clinically unrecognizable, and the detectable preinvasive phase may be absent, as with some nodular melanomas, or too short in duration to be detected by periodic skin examination.</p><p class="headingAnchor" id="H2781740601"><span class="h1">EFFECTIVENESS OF SCREENING</span></p><p class="headingAnchor" id="H4134342639"><span class="h2">Overview of available data</span><span class="headingEndMark"> — </span>Randomized trial data are not available for melanoma screening, and therefore it is not certain that screening will result in decreased mortality due to melanoma [<a href="#rid21">21,22</a>]. A randomized trial of screening is likely not feasible, as it has been estimated that approximately 800,000 participants would be required to detect a difference in mortality because of the relatively low melanoma mortality rate [<a href="#rid21">21</a>].</p><p>Data are available from observational studies; however, in general, observational studies are subject to potential study bias (lead time bias, length bias) (see  <a class="medical medical_review" href="/d/html/7570.html" rel="external">"Evidence-based approach to prevention", section on 'Special biases'</a>). Further, the observational studies about melanoma screening vary as to who performed the screening, which target populations were screened, and which components of care were included as screening. For example, in some studies screening was directed at all individuals (eg, population-based screening), and in others screening was targeted to only those with specific risk factors. Some studies of "screening" for melanoma extended their scope to include forms of early diagnosis (examination of patients with a concern about a skin lesion, termed “lesion directed screening” but not “screening” by a clinician of an asymptomatic individual), and some studies incorporated patient education programs in addition to screening [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H2136203758"><span class="h2">Clinician screening</span></p><p class="headingAnchor" id="H2018197003"><span class="h3">Uncertain effect on mortality</span><span class="headingEndMark"> — </span>The best observational data about the effect of clinician screening on mortality rates include a large year-long population screening effort in Germany, the Skin Cancer Research to Provide Evidence for Effectiveness of Screening in Northern Germany project (SCREEN), in which clinician skin examination was associated with melanoma mortality reduction five years after the screening program, although the mortality reduction did not persist in longer-term follow-up [<a href="#rid39">39-42</a>].</p><p>The SCREEN pilot study began with a program to generate intensive public and professional awareness, followed by offers for screening by general practitioners. Among 1.9 million adults, 360,000 chose to be screened (three-quarters of participants choose screening by a non-dermatologist trained in skin examination). Overall, 620 persons needed to be screened to detect one melanoma. Ninety percent of melanomas detected by screening were less than 1 mm thick. Five years following the screening effort, despite a screening participation rate under 20 percent, mortality from melanoma among adults in the pilot program area was nearly 50 percent lower than in the rest of Germany and contiguous Denmark and was lower than expected based on historical rates. However, the mortality decline seen at the five-year mark was not sustained; two years later, mortality rates returned to the pre-screening level [<a href="#rid43">43</a>]. Further, a subsequent analysis raised questions about the reliability of the ICD-10 codes used to determine cause of mortality in the study; during the time when melanoma deaths decreased, there was an unexplained increase in codes indicating deaths due to malignant neoplasms of ill-defined, secondary, and unspecified sites [<a href="#rid43">43</a>]. The pilot study also had methodological limitations in that it lacked randomization, an internal control group, and individual level data [<a href="#rid44">44</a>].</p><p>In contrast to the mortality benefit observed at five years in the SCREEN pilot study, a subsequent nationwide program in Germany to offer adults aged ≥35 years skin cancer screening every two years demonstrated no measurable decline in melanoma mortality through five years of follow-up [<a href="#rid42">42,43,45-47</a>].</p><p>Other observational studies have not identified an association between clinician examination and survival from melanoma. A 20-year survival analysis of a large cohort of cases confirmed the lack of association between skin self-examination, clinician examination, or casual skin examination and death from melanoma [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H446426719"><span class="h3">Effect on melanoma thickness</span><span class="headingEndMark"> — </span>Observational studies have consistently shown that melanomas detected by clinicians during a skin examination are thinner than those found by patients or their significant others [<a href="#rid31">31,49-59</a>]. Because melanoma thickness is associated with prognosis (thinner melanomas have a substantially more favorable prognosis), it has been considered a surrogate marker for melanoma mortality. Identification of thinner melanomas thus supports a benefit of screening.</p><p>Examples of screening effect on thickness include:</p><p class="bulletIndent1"><span class="glyph">●</span>A population-based case-control study in Queensland, Australia showed that, when compared with unscreened patients, primary care clinician screening was associated with thinner melanoma lesions [<a href="#rid53">53</a>]. Melanoma lesion thickness was thinner among patients who reported having a full skin examination by a clinician during the three years preceding a diagnosis of melanoma, compared with those who had not had a skin examination. Screened patients had a 14 percent lower risk for a lesion &gt;0.75 mm thick. The decrease in risk was greatest for the thickest melanomas (risk reduction 40 percent for lesions ≥3 mm).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, in the Western Pennsylvania primary care physician-based screening intervention, clinician screening was associated with a higher rate of melanoma diagnoses, including increased diagnoses of stage T1 (≤1 mm) melanoma and melanomas in situ, but not thicker melanomas [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H2539924123"><span class="h3">Uncertain effect of clinician specialty and training</span><span class="headingEndMark"> — </span>Study results vary as to whether there are differences between the results of skin examination by dermatologists and primary care clinicians.</p><p>Some studies show that detection by a dermatologist rather than a non-dermatologist results in thinner and earlier-stage lesion detection [<a href="#rid54">54,61,62</a>]. Other studies found no difference between dermatologist and primary care clinician examination [<a href="#rid63">63</a>]. A systematic review of 32 studies concluded that the available data were inadequate to demonstrate differences between dermatologists and primary care physicians in diagnostic accuracy of lesions suggestive of melanoma [<a href="#rid64">64</a>].</p><p>The value of clinician training to detect melanoma has been demonstrated in several studies. Few medical professionals have specific education in early detection of melanoma [<a href="#rid65">65-69</a>]. Dermatologists have been found to be better at detecting melanoma by photographs than primary care physicians [<a href="#rid70">70</a>]. In a population-based screening program in the United States, the rate of melanoma diagnosis rose almost 80 percent among patients screened at practices with the highest proportion of providers trained using INFORMED (INternet curriculum FOR Melanoma Early Detection), an online educational system for primary care clinicians [<a href="#rid67">67,71-73</a>]. Outcomes among patients could not be directly compared due to the absence of individual patient-level data.</p><p class="headingAnchor" id="H3015555322"><span class="h2">Patient self-examination efficacy</span><span class="headingEndMark"> — </span>A few retrospective and case-control studies have associated patient self-examination of the skin with the detection of thinner tumors, a reduced risk of advanced melanoma, and reduction in mortality [<a href="#rid54">54,58,74-76</a>]. However, the studies have limitations, and overall, data in support of self-examination are limited.</p><p>A prospective workplace time series conducted in northern California from 1965 to 1996, involving a pre-awareness, education, and skin screening program, resulted in a reduction in the incidence of thicker melanoma and a lower-than-expected death rate compared with the statewide cancer registry statistics over the time period assessed [<a href="#rid77">77</a>].</p><p>Lesion-directed evaluation, in which clinicians examine lesions identified by patients using predetermined criteria, required less time and resulted in similar melanoma detection rates as total skin examination in a study that compared total body examination by experienced dermatologists in two sociodemographically similar regions in Belgium [<a href="#rid78">78</a>]. Lesion-directed evaluation showed a similar detection rate (2.3 versus 3.2 percent) but was 5.6 times less time-consuming. Further investigation of public education leading to lesion-directed evaluation may show a cost-benefit for patients and practitioners.</p><p>However, even many individuals at a high risk of melanoma do not do skin self-examination [<a href="#rid79">79,80</a>]. Rates of self-examination may be increased by programs that involve computer-assisted patient education, telecommunication reminders, partner hands-on tutorials, partner involvement in skin self-examination, cues and aids, brief counseling and follow-up telephone call, and tailored feedback letters [<a href="#rid81">81-83</a>]. In a two-year randomized trial including 494 melanoma patients and their partners, the effect of a structured educational intervention on the performance of skin self-examination and early detection of new melanomas was examined [<a href="#rid82">82</a>]. During the two years of follow-up, a total of 66 patients (13.4 percent) developed a new melanoma. In the group receiving the intervention, 43 melanomas (33 in situ) were identified by patients or their partners and 10 by clinicians; by contrast, all 16 melanomas in the control group were identified by clinicians and none by the patient-partner pairs.</p><p>A survey tool for patients to assess their awareness of freckling, moles, and atypical nevi may help high-risk patients become aware of their risk status by identifying their own skin findings that place them at increased risk [<a href="#rid16">16</a>]. With this tool, concordance between the patient's report and the clinician’s skin examination, measured on a scale where 1 = perfect agreement, was good for freckles (0.67), moderate to good for moles (0.60), and moderate for atypical nevi (0.43).</p><p class="headingAnchor" id="H3223622836"><span class="h2">Feasibility of community screening</span><span class="headingEndMark"> — </span>A randomized trial of population screening in Australia, where the rate of melanoma is higher than in most other countries, showed that community-based melanoma screening programs are feasible [<a href="#rid84">84</a>]. The trial included three components: community education to provide information about melanoma and screening, education and support for medical practitioners to improve clinician skills, and free skin-screening services. The study design called for randomizing 44 Queensland communities, but this was not completed due to lack of funding. Rates of performance of the whole-body skin cancer examination were measured by surveys of residents [<a href="#rid84">84,85</a>]. Baseline screening rates were similar in intervention and control towns (11.2 and 11.3 percent, respectively). At two years, screening rates rose to 35 percent in intervention towns compared with 14 percent in control communities [<a href="#rid86">86</a>]. More than 16,000 whole-body examinations were performed by general practitioners and special screening services, with skin cancer detected in 2.4 percent (33 melanomas, 259 basal cell carcinomas, and 97 squamous cell carcinomas) [<a href="#rid87">87</a>]. The specificity of the skin examination for melanoma was 86 percent. As this study was not completed due to lack of funding, the potential benefits versus harms of community screening remain uncertain.</p><p class="headingAnchor" id="H578493563"><span class="h1">HARMS OF SCREENING</span><span class="headingEndMark"> — </span>The harms of screening for melanoma include the potential that false-positive findings on skin examination will lead to an increased number of dermatology referrals and unnecessary biopsies, with resulting anxiety, scarring, and expense and the possibility of overdiagnosis (ie, the diagnosis of melanoma that is either non-growing or so slow-growing that it would never become clinically meaningful during the patient’s lifetime). The diagnosis of melanocytic lesions is also challenging, with substantial variability noted among pathologists [<a href="#rid88">88</a>]. Screening also has "opportunity costs,” ie, the recognition that a clinician's time is a finite resource that is best spent on care that provides the greatest opportunities for benefits to the patient and is of known effectiveness.</p><p class="headingAnchor" id="H638391646"><span class="h2">False-positive screens</span><span class="headingEndMark"> — </span>As the majority of the population will not be diagnosed with melanoma, the potential for false-positive screens is of concern when considering mass screening programs. However, data are limited on this topic. A few small studies suggested that screening by primary care clinicians trained in skin cancer screening was not associated with an increase in utilization of dermatology services. In a United States population-based melanoma screening program, 1572 patients were screened by primary care clinicians trained using an online educational system. Screening was associated with increased rates of melanoma diagnosis but was not associated with increased rates of dermatology visits, biopsies, or surgeries [<a href="#rid67">67,71-73</a>]. Similarly, in a small Veterans Affairs (VA) health care system pilot study, trained primary care clinicians offered screening to 258 patients; 189 accepted screening, and there were no differences between the number of dermatology referrals or skin biopsies in the pre- and post-training periods [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H214715150"><span class="h2">Psychosocial impact of screening</span><span class="headingEndMark"> — </span>In the VA study, the psychosocial impact of screening for melanoma was evaluated; a sample of screened patients reported positive reactions to clinician screening (though some patients preferred dermatologist examination), lack of psychosocial harms (eg, discomfort undressing, distress over referrals), and appreciation of screening as a valuable addition to their health care [<a href="#rid90">90</a>]. The population-based screening program surveyed a small sample of patients who were biopsied as a result of screening; biopsied patients reported no difference in anxiety or depression compared with patients screened but not biopsied using standardized and validated measures of anxiety and depression [<a href="#rid91">91</a>]. Larger studies are needed to more clearly define the harms of melanoma screening.</p><p class="headingAnchor" id="H482973041"><span class="h2">Variability of pathologic diagnosis</span><span class="headingEndMark"> — </span>Skin cancer screening will only be effective if the subsequent diagnosis is accurate, yet the assessment and classification of melanocytic skin lesions is challenging for pathologists. One study found that 23 percent of skin biopsies in the United States are of melanocytic skin lesions [<a href="#rid92">92</a>], highlighting the importance of the pathologists’ diagnosis. The pathologic thresholds to label morphologic changes as cancer have fallen over time [<a href="#rid93">93</a>], and extensive variability among pathologists has been noted [<a href="#rid94">94</a>]. For example, diagnoses of melanoma in situ and early-stage invasive melanoma were neither reproducible nor accurate in a large study of 187 pathologists [<a href="#rid88">88,95</a>]. In addition to acknowledging the uncertainty in pathology reports, other suggestions have included use of standardized classification systems to improve communication [<a href="#rid96">96,97</a>], having skin biopsies interpreted by experienced board certified or fellowship trained pathologists [<a href="#rid98">98</a>], or obtaining second opinions [<a href="#rid99">99,100</a>].</p><p class="headingAnchor" id="H4067505511"><span class="h2">Overdiagnosis</span><span class="headingEndMark"> — </span>Data quantifying the potential harms of melanoma screening are scant [<a href="#rid83">83</a>]; however, the United States Surveillance Epidemiology and End Results (SEER) Program results indicate an increase in detection of early-stage melanoma without benefit on mortality [<a href="#rid101">101</a>]. This discrepancy suggests overdiagnosis, in which lesions detected only as a result of screening would not have led to clinically significant symptoms. Overdiagnosis can lead to treatment of biologically indolent lesions with increased patient morbidity and health-related costs. (See  <a class="medical medical_review" href="/d/html/7570.html" rel="external">"Evidence-based approach to prevention", section on 'Risk of overdiagnosis (pseudodisease) in cancer screening'</a>.)</p><p>Specifically, analysis of SEER data suggests that, despite efforts to improve screening and detection, melanoma detection practices have <strong>not</strong> lowered rates of prognostically unfavorable tumors [<a href="#rid101">101-105</a>]. Based on SEER data from 1986 to 2001, there was a 2.5-fold increase in skin biopsy rates among patients aged 65 and older [<a href="#rid101">101</a>]. This was associated with increased detection of in situ and early-stage invasive melanoma but not increased detection of advanced melanoma, and melanoma mortality rates remained stable during the reporting period [<a href="#rid101">101</a>]. Analysis of SEER data from the subsequent eight years similarly found increases in the rates of skin biopsy and an associated increase in melanoma in situ detection<em> </em>[<a href="#rid102">102</a>]. The incidence of invasive melanoma initially increased but then decreased, and the associations between skin biopsy and invasive melanoma incidence were complex and varied in state-level analyses.</p><p class="headingAnchor" id="H36397644"><span class="h1">INVESTIGATIONAL APPROACHES</span><span class="headingEndMark"> — </span>In addition to visual screening, research is ongoing to find imaging and molecular technologies to detect melanoma at an early stage when cure is feasible. Studies of patients known to have melanoma have led to identification of a set of autoantibody biomarkers. In a study of 124 melanoma patients and 121 healthy controls, the panel of 10 autoantibodies to tumor-associated antigens had a sensitivity of 79 percent and a specificity of 84 percent for primary melanoma detection [<a href="#rid106">106</a>]. This small, early report of a blood test method has not been validated or studied in a screening population. Additional studies are therefore needed to determine if use of such a biomarker panel would be beneficial or harmful if used in routine population-based screening.</p><p class="headingAnchor" id="H1163817014"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a>.)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>Several websites describing self-examination are available for patient access [<a href="#rid107">107,108</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aad.org%2Fpublic%2Fdiseases%2Fskin-cancer%2Ffind%2Fcheck-skin&amp;token=0tl8118OS4vI1lYbBvphjg09Ksxt9ZAg0nJugScmULAjOf1w19hKfCOVEApfUsuRFo1g0WzAvm9RVwLTBIIjB901PDsmG5JK3zd9P0jufmw%3D&amp;TOPIC_ID=4845" target="_blank">The American Academy of Dermatology</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.skincancer.org%2Fearly-detection%2F&amp;token=FWNID0ZRoEvvwjKjY4KwHR%2FIvNY3kYF6JqVz27ZRSvGWdwcbLKXYHqZiiXZrdqZLE6AxRrQqkNG8EfrDLkUyxw%3D%3D&amp;TOPIC_ID=4845" target="_blank">The Skin Cancer Foundation</a></p><p></p><p>In addition, UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>The Basics topics (see  <a class="medical medical_basics" href="/d/html/15499.html" rel="external">"Patient education: Melanoma skin cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/889.html" rel="external">"Patient education: Melanoma treatment; localized melanoma (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/892.html" rel="external">"Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>No randomized trials have been conducted to establish the efficacy of screening for melanoma on mortality reduction, but observational studies evaluating the impact on tumor thickness or mortality are encouraging. Although the majority of melanomas are initially detected by patients themselves, melanomas detected by clinicians have consistently been shown to be thinner than those found by patients or their significant others. (See <a class="local">'Effectiveness of screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The harms of screening for melanoma include the potential that false-positive findings on skin examination will lead to an increased number of dermatology referrals and unnecessary biopsies, with resulting anxiety, scarring, and expense, and the possibility of overdiagnosis (ie, the diagnosis of melanoma that is either non-growing or so slow-growing that it would never become clinically meaningful during the patient’s lifetime). (See <a class="local">'Harms of screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with certain risk factors are at high risk of developing or dying from melanoma:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>White adults age 50 and above.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Total nevus count above 50 and/or presence of large (atypical/dysplastic) nevi.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Personal history of skin cancer.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>immunosuppression, particularly chronic use of immunosuppressive medications such as those used by organ transplant recipients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Very sun-sensitive individuals and those with “red hair phenotype” (eg, light skin pigmentation, red or blond hair color, high-density freckling, and light eye color [green, hazel, blue]).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Family history of melanoma in one or more first-degree relatives or in more than one second-degree relative on the same side of the lineage. Those with at least three affected members (including one or more first-degree relatives) on one side of the family are at very high risk. (See <a class="local">'High-risk patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For high-risk patients, we suggest screening for melanoma (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Screening involves a full-body skin examination performed yearly by a clinician who has had appropriate training in the identification of melanoma (clinician examination) as well as education for patients about melanoma risk factors and advice to alert their clinician if self-examination detects changing moles or other suspicious skin lesions. (See <a class="local">'High-risk patients'</a> above and <a class="local">'Clinician screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the general population outside of these high-risk groups, we do <strong>not</strong> routinely screen with clinician skin examination. However, for patients without identified increased risk, clinicians should remain vigilant for any suspicious lesions identified in the course of a routine or sick visit (opportunistic case finding). A focused skin examination of the palms, soles, and digits may be of value in people with darker skin, who are more likely to have acral melanoma. All patients should be aware of melanoma clinical warning signs and bring any concerning lesions to the clinician’s attention. (See <a class="local">'Non-high-risk patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Certain tools can help clinicians and patients identify lesions to evaluate further for melanoma. These include the "ugly duckling" sign, the ABCDE rule of melanoma  (<a class="graphic graphic_picture graphicRef52518" href="/d/graphic/52518.html" rel="external">picture 1</a>), and the Glasgow revised seven-point checklist. Further detail is provided elsewhere (see  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'Clinical prediction rules'</a>). Detecting melanoma in children is discussed separately. (See  <a class="medical medical_review" href="/d/html/101324.html" rel="external">"Melanoma in children", section on 'Physical examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When suspicious lesions are detected, appropriate referrals are warranted (to a dermatologist where possible) for further evaluation of all such lesions. (See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis", section on 'Management of suspicious lesions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients should be educated about the importance of sun protection for melanoma prevention. (See  <a class="medical medical_review" href="/d/html/4842.html" rel="external">"Primary prevention of melanoma", section on 'Sun protection'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kohler BA, Sherman RL, Howlader N, et al. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst 2015; 107:djv048.</a></li><li><a class="nounderline abstract_t">Kang S, Barnhill RL, Mihm MC Jr, et al. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol 1994; 130:999.</a></li><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68:7.</a></li><li class="breakAll">https://seer.cancer.gov/statfacts/html/melan.html (Accessed on June 22, 2021).</li><li><a class="nounderline abstract_t">Welch HG, Mazer BL, Adamson AS. The Rapid Rise in Cutaneous Melanoma Diagnoses. N Engl J Med 2021; 384:72.</a></li><li><a class="nounderline abstract_t">Lopes FCPS, Sleiman MG, Sebastian K, et al. UV Exposure and the Risk of Cutaneous Melanoma in Skin of Color: A Systematic Review. JAMA Dermatol 2021; 157:213.</a></li><li class="breakAll">National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: Incidence and mortality by race/ethnicity, CSR 1975-2014. Available at: https://seer.cancer.gov/csr/1975_2014/results_merged/topic_race_ethnicity.pdf (Accessed on September 04, 2017).</li><li class="breakAll">National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: Table 16.8, 5-year relative survival (percent) by year of diagnosis. Available at: https://seer.cancer.gov/csr/1975_2014/browse_csr.php?sectionSEL=16&amp;pageSEL=sect_16_table.08.html (Accessed on September 04, 2017).</li><li><a class="nounderline abstract_t">Cockburn MG, Zadnick J, Deapen D. Developing epidemic of melanoma in the Hispanic population of California. Cancer 2006; 106:1162.</a></li><li><a class="nounderline abstract_t">Cormier JN, Xing Y, Ding M, et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med 2006; 166:1907.</a></li><li><a class="nounderline abstract_t">Myles ZM, Buchanan N, King JB, et al. Anatomic distribution of malignant melanoma on the non-Hispanic black patient, 1998-2007. Arch Dermatol 2012; 148:797.</a></li><li><a class="nounderline abstract_t">Pollitt RA, Clarke CA, Swetter SM, et al. The expanding melanoma burden in California hispanics: Importance of socioeconomic distribution, histologic subtype, and anatomic location. Cancer 2011; 117:152.</a></li><li><a class="nounderline abstract_t">Coups EJ, Stapleton JL, Hudson SV, et al. Skin cancer screening among Hispanic adults in the United States: results from the 2010 National Health Interview Survey. Arch Dermatol 2012; 148:861.</a></li><li><a class="nounderline abstract_t">Carter TM, Strassle PD, Ollila DW, et al. Does acral lentiginous melanoma subtype account for differences in patterns of care in Black patients? Am J Surg 2021; 221:706.</a></li><li><a class="nounderline abstract_t">Fears TR, Guerry D 4th, Pfeiffer RM, et al. Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol 2006; 24:3590.</a></li><li><a class="nounderline abstract_t">Jackson A, Wilkinson C, Ranger M, et al. Can primary prevention or selective screening for melanoma be more precisely targeted through general practice? A prospective study to validate a self administered risk score. BMJ 1998; 316:34.</a></li><li><a class="nounderline abstract_t">Mar V, Wolfe R, Kelly JW. Predicting melanoma risk for the Australian population. Australas J Dermatol 2011; 52:109.</a></li><li><a class="nounderline abstract_t">Fortes C, Mastroeni S, Bakos L, et al. Identifying individuals at high risk of melanoma: a simple tool. Eur J Cancer Prev 2010; 19:393.</a></li><li><a class="nounderline abstract_t">Cho E, Rosner BA, Feskanich D, Colditz GA. Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 2005; 23:2669.</a></li><li class="breakAll">National Cancer Institute. The melanoma risk assessment tool. Available at: https://www.cancer.gov/melanomarisktool/ (Accessed on June 19, 2017).</li><li><a class="nounderline abstract_t">Wolff T, Tai E, Miller T. Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150:194.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2023; 329:1290.</a></li><li class="breakAll">Australian Cancer Network. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. National Health and Medical Research Council (NHMRC), Canberra, 2008.</li><li class="breakAll">Canadian Cancer Society. Skin exam. Available at: https://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/tests-and-procedures/skin-exam/?region=on (Accessed on June 22, 2021).</li><li><a class="nounderline abstract_t">Bigby M. Why the evidence for skin cancer screening is insufficient: lessons from prostate cancer screening. Arch Dermatol 2010; 146:322.</a></li><li class="breakAll">Cancer Council Australia. Clinical practice guidelines. Available at: http://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/ClinicalPracticeGuidelines-ManagementofMelanoma.pdf (Accessed on June 28, 2017).</li><li class="breakAll">Langley RG, Fitzpatrick TB, Sober AJ. Clinical characteristics. In: Cutaneous Melanoma, Balch CM, Houghton AN, Sober AJ, Soong SJ (Eds), Quality Medical Publishing, 1998. p.81.</li><li><a class="nounderline abstract_t">Pruthi DK, Guilfoyle R, Nugent Z, et al. Incidence and anatomic presentation of cutaneous malignant melanoma in central Canada during a 50-year period: 1956 to 2005. J Am Acad Dermatol 2009; 61:44.</a></li><li><a class="nounderline abstract_t">Juhl AL, Byers TE, Robinson WA, et al. The anatomic distribution of melanoma and relationships with childhood nevus distribution in Colorado. Melanoma Res 2009; 19:252.</a></li><li><a class="nounderline abstract_t">Harman KE, Fuller LC, Salisbury JR, et al. Trends in the presentation of cutaneous malignant melanoma over three decades at King's College Hospital, London. Clin Exp Dermatol 2004; 29:563.</a></li><li><a class="nounderline abstract_t">Swetter SM, Johnson TM, Miller DR, et al. Melanoma in middle-aged and older men: a multi-institutional survey study of factors related to tumor thickness. Arch Dermatol 2009; 145:397.</a></li><li><a class="nounderline abstract_t">Mayer JE, Swetter SM, Fu T, Geller AC. Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions: Part I. Epidemiology, high-risk groups, clinical strategies, and diagnostic technology. J Am Acad Dermatol 2014; 71:599.e1.</a></li><li><a class="nounderline abstract_t">Rhodes AR, Weinstock MA, Fitzpatrick TB, et al. Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA 1987; 258:3146.</a></li><li class="breakAll">Balch CM, Soong SJ, Shaw HM, et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Cutaneous Melanoma, Balch CM, Houghton AN, Milton GW, et al (Eds), JB Lippincott Company, Philadelphia 1992. p.165.</li><li class="breakAll">Koh HK, Geller AC, Lew RA. Melanoma. In: Cancer screening: Theory and practice, Kramer BS, Gohagan JK, Prorok PC (Eds), Marcel Dekker, New York 1999. p.379.</li><li><a class="nounderline abstract_t">MacKie RM. Thickness and delay in diagnosis of melanoma: how far can we go? Arch Dermatol 1999; 135:339.</a></li><li><a class="nounderline abstract_t">Elwood JM. Screening for melanoma and options for its evaluation [see comment]. J Med Screen 1994; 1:22.</a></li><li><a class="nounderline abstract_t">Burton RC, Armstrong BK. Recent incidence trends imply a nonmetastasizing form of invasive melanoma. Melanoma Res 1994; 4:107.</a></li><li><a class="nounderline abstract_t">Breitbart EW, Waldmann A, Nolte S, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012; 66:201.</a></li><li><a class="nounderline abstract_t">Waldmann A, Nolte S, Geller AC, et al. Frequency of excisions and yields of malignant skin tumors in a population-based screening intervention of 360,288 whole-body examinations. Arch Dermatol 2012; 148:903.</a></li><li><a class="nounderline abstract_t">Katalinic A, Waldmann A, Weinstock MA, et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. Cancer 2012; 118:5395.</a></li><li><a class="nounderline abstract_t">Katalinic A, Eisemann N, Waldmann A. Skin Cancer Screening in Germany. Documenting Melanoma Incidence and Mortality From 2008 to 2013. Dtsch Arztebl Int 2015; 112:629.</a></li><li><a class="nounderline abstract_t">Stang A, Jöckel KH. Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany. Cancer 2016; 122:432.</a></li><li class="breakAll">National Cancer Institute. Skin cancer screening (PDQ) - health professional version. Available at: www.cancer.gov/types/skin/hp/skin-screening-pdq#cit/section_2.28 (Accessed on June 22, 2021).</li><li><a class="nounderline abstract_t">Choudhury K, Volkmer B, Greinert R, et al. Effectiveness of skin cancer screening programmes. Br J Dermatol 2012; 167 Suppl 2:94.</a></li><li><a class="nounderline abstract_t">Boniol M, Autier P, Gandini S. Melanoma mortality following skin cancer screening in Germany. BMJ Open 2015; 5:e008158.</a></li><li><a class="nounderline abstract_t">Kaiser M, Schiller J, Schreckenberger C. The effectiveness of a population-based skin cancer screening program: evidence from Germany. Eur J Health Econ 2018; 19:355.</a></li><li><a class="nounderline abstract_t">Paddock LE, Lu SE, Bandera EV, et al. Skin self-examination and long-term melanoma survival. Melanoma Res 2016; 26:401.</a></li><li><a class="nounderline abstract_t">Smith RA, Brooks D, Cokkinides V, et al. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin 2013; 63:88.</a></li><li><a class="nounderline abstract_t">Durbec F, Vitry F, Granel-Brocard F, et al. The role of circumstances of diagnosis and access to dermatological care in early diagnosis of cutaneous melanoma: a population-based study in France. Arch Dermatol 2010; 146:240.</a></li><li><a class="nounderline abstract_t">Geller AC, Johnson TM, Miller DR, et al. Factors associated with physician discovery of early melanoma in middle-aged and older men. Arch Dermatol 2009; 145:409.</a></li><li><a class="nounderline abstract_t">Epstein DS, Lange JR, Gruber SB, et al. Is physician detection associated with thinner melanomas? JAMA 1999; 281:640.</a></li><li><a class="nounderline abstract_t">Aitken JF, Elwood M, Baade PD, et al. Clinical whole-body skin examination reduces the incidence of thick melanomas. Int J Cancer 2010; 126:450.</a></li><li><a class="nounderline abstract_t">Carli P, De Giorgi V, Palli D, et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003; 139:607.</a></li><li><a class="nounderline abstract_t">Kantor J, Kantor DE. Routine dermatologist-performed full-body skin examination and early melanoma detection. Arch Dermatol 2009; 145:873.</a></li><li><a class="nounderline abstract_t">Terushkin V, Halpern AC. Melanoma early detection. Hematol Oncol Clin North Am 2009; 23:481.</a></li><li><a class="nounderline abstract_t">Kovalyshyn I, Dusza SW, Siamas K, et al. The impact of physician screening on melanoma detection. Arch Dermatol 2011; 147:1269.</a></li><li><a class="nounderline abstract_t">Swetter SM, Pollitt RA, Johnson TM, et al. Behavioral determinants of successful early melanoma detection: role of self and physician skin examination. Cancer 2012; 118:3725.</a></li><li><a class="nounderline abstract_t">Geller AC, Elwood M, Swetter SM, et al. Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia. Cancer 2009; 115:1318.</a></li><li><a class="nounderline abstract_t">Ferris LK, Saul MI, Lin Y, et al. A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes. JAMA Oncol 2017; 3:1112.</a></li><li><a class="nounderline abstract_t">Pennie ML, Soon SL, Risser JB, et al. Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist vs a nondermatologist. Arch Dermatol 2007; 143:488.</a></li><li><a class="nounderline abstract_t">Gerbert B, Maurer T, Berger T, et al. Primary care physicians as gatekeepers in managed care. Primary care physicians' and dermatologists' skills at secondary prevention of skin cancer. Arch Dermatol 1996; 132:1030.</a></li><li><a class="nounderline abstract_t">Roetzheim RG, Lee JH, Ferrante JM, et al. The influence of dermatologist and primary care physician visits on melanoma outcomes among Medicare beneficiaries. J Am Board Fam Med 2013; 26:637.</a></li><li><a class="nounderline abstract_t">Chen SC, Bravata DM, Weil E, Olkin I. A comparison of dermatologists' and primary care physicians' accuracy in diagnosing melanoma: a systematic review. Arch Dermatol 2001; 137:1627.</a></li><li><a class="nounderline abstract_t">Wise E, Singh D, Moore M, et al. Rates of skin cancer screening and prevention counseling by US medical residents. Arch Dermatol 2009; 145:1131.</a></li><li><a class="nounderline abstract_t">Tsao H, Weinstock MA. Visual Inspection and the US Preventive Services Task Force Recommendation on Skin Cancer Screening. JAMA 2016; 316:398.</a></li><li><a class="nounderline abstract_t">Eide MJ, Asgari MM, Fletcher SW, et al. Effects on skills and practice from a web-based skin cancer course for primary care providers. J Am Board Fam Med 2013; 26:648.</a></li><li><a class="nounderline abstract_t">Grange F, Barbe C, Mas L, et al. The role of general practitioners in diagnosis of cutaneous melanoma: a population-based study in France. Br J Dermatol 2012; 167:1351.</a></li><li><a class="nounderline abstract_t">Grange F, Woronoff AS, Bera R, et al. Efficacy of a general practitioner training campaign for early detection of melanoma in France. Br J Dermatol 2014; 170:123.</a></li><li><a class="nounderline abstract_t">Chen SC, Pennie ML, Kolm P, et al. Diagnosing and managing cutaneous pigmented lesions: primary care physicians versus dermatologists. J Gen Intern Med 2006; 21:678.</a></li><li class="breakAll">visualDx. Skin cancer education. Available at: https://www.visualdx.com/skin-cancer-education/ (Accessed on June 22, 2021).</li><li><a class="nounderline abstract_t">Shaikh WR, Geller A, Alexander G, et al. Developing an interactive web-based learning program on skin cancer: the learning experiences of clinical educators. J Cancer Educ 2012; 27:709.</a></li><li><a class="nounderline abstract_t">Weinstock MA, Ferris LK, Saul MI, et al. Downstream consequences of melanoma screening in a community practice setting: First results. Cancer 2016; 122:3152.</a></li><li><a class="nounderline abstract_t">Pollitt RA, Geller AC, Brooks DR, et al. Efficacy of skin self-examination practices for early melanoma detection. Cancer Epidemiol Biomarkers Prev 2009; 18:3018.</a></li><li><a class="nounderline abstract_t">Talaganis JA, Biello K, Plaka M, et al. Demographic, behavioural and physician-related determinants of early melanoma detection in a low-incidence population. Br J Dermatol 2014; 171:832.</a></li><li><a class="nounderline abstract_t">Berwick M, Begg CB, Fine JA, et al. Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst 1996; 88:17.</a></li><li><a class="nounderline abstract_t">Schneider JS, Moore DH 2nd, Mendelsohn ML. Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996. J Am Acad Dermatol 2008; 58:741.</a></li><li><a class="nounderline abstract_t">Hoorens I, Vossaert K, Pil L, et al. Total-Body Examination vs Lesion-Directed Skin Cancer Screening. JAMA Dermatol 2016; 152:27.</a></li><li><a class="nounderline abstract_t">Aitken JF, Janda M, Lowe JB, et al. Prevalence of whole-body skin self-examination in a population at high risk for skin cancer (Australia). Cancer Causes Control 2004; 15:453.</a></li><li><a class="nounderline abstract_t">Kasparian NA, McLoone JK, Meiser B, et al. Skin cancer screening behaviours among individuals with a strong family history of malignant melanoma. Br J Cancer 2010; 103:1502.</a></li><li><a class="nounderline abstract_t">Aneja S, Brimhall AK, Kast DR, et al. Improvement in Patient Performance of Skin Self-examinations After Intervention With Interactive Education and Telecommunication Reminders: A Randomized Controlled Study. Arch Dermatol 2012; 148:1266.</a></li><li><a class="nounderline abstract_t">Robinson JK, Wayne JD, Martini MC, et al. Early Detection of New Melanomas by Patients With Melanoma and Their Partners Using a Structured Skin Self-examination Skills Training Intervention: A Randomized Clinical Trial. JAMA Dermatol 2016; 152:979.</a></li><li><a class="nounderline abstract_t">Weinstock MA, Risica PM, Martin RA, et al. Melanoma early detection with thorough skin self-examination: the "Check It Out" randomized trial. Am J Prev Med 2007; 32:517.</a></li><li><a class="nounderline abstract_t">Lowe JB, Ball J, Lynch BM, et al. Acceptability and feasibility of a community-based screening programme for melanoma in Australia. Health Promot Int 2004; 19:437.</a></li><li><a class="nounderline abstract_t">Aitken JF, Elwood JM, Lowe JB, et al. A randomised trial of population screening for melanoma. J Med Screen 2002; 9:33.</a></li><li><a class="nounderline abstract_t">Aitken JF, Youl PH, Janda M, et al. Increase in skin cancer screening during a community-based randomized intervention trial. Int J Cancer 2006; 118:1010.</a></li><li><a class="nounderline abstract_t">Aitken JF, Janda M, Elwood M, et al. Clinical outcomes from skin screening clinics within a community-based melanoma screening program. J Am Acad Dermatol 2006; 54:105.</a></li><li><a class="nounderline abstract_t">Elmore JG, Barnhill RL, Elder DE, et al. Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ 2017; 357:j2813.</a></li><li><a class="nounderline abstract_t">Swetter SM, Chang J, Shaub AR, et al. Primary Care-Based Skin Cancer Screening in a Veterans Affairs Health Care System. JAMA Dermatol 2017; 153:797.</a></li><li><a class="nounderline abstract_t">Shaub AR, Lewis ET, Swetter SM. Patient Perceptions of Primary Care-Based Skin Cancer Screening. JAMA Dermatol 2017; 153:1192.</a></li><li><a class="nounderline abstract_t">Matthews NH, Risica PM, Ferris LK, et al. Psychosocial impact of skin biopsies in the setting of melanoma screening: a cross-sectional survey. Br J Dermatol 2019; 180:664.</a></li><li><a class="nounderline abstract_t">Lott JP, Boudreau DM, Barnhill RL, et al. Population-Based Analysis of Histologically Confirmed Melanocytic Proliferations Using Natural Language Processing. JAMA Dermatol 2018; 154:24.</a></li><li><a class="nounderline abstract_t">Frangos JE, Duncan LM, Piris A, et al. Increased diagnosis of thin superficial spreading melanomas: A 20-year study. J Am Acad Dermatol 2012; 67:387.</a></li><li><a class="nounderline abstract_t">Glusac EJ. The melanoma 'epidemic', a dermatopathologist's perspective. J Cutan Pathol 2011; 38:264.</a></li><li><a class="nounderline abstract_t">Elmore JG, Elder DE, Barnhill RL, et al. Concordance and Reproducibility of Melanoma Staging According to the 7th vs 8th Edition of the AJCC Cancer Staging Manual. JAMA Netw Open 2018; 1.</a></li><li><a class="nounderline abstract_t">Radick AC, Reisch LM, Shucard HL, et al. Terminology for melanocytic skin lesions and the MPATH-Dx classification schema: A survey of dermatopathologists. J Cutan Pathol 2021; 48:733.</a></li><li><a class="nounderline abstract_t">Barnhill RL, Elder DE, Piepkorn MW, et al. Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement. JAMA Netw Open 2023; 6:e2250613.</a></li><li><a class="nounderline abstract_t">Elder DE, Piepkorn MW, Barnhill RL, et al. Pathologist characteristics associated with accuracy and reproducibility of melanocytic skin lesion interpretation. J Am Acad Dermatol 2018; 79:52.</a></li><li><a class="nounderline abstract_t">Geller BM, Frederick PD, Knezevich SR, et al. Pathologists' Use of Second Opinions in Interpretation of Melanocytic Cutaneous Lesions: Policies, Practices, and Perceptions. Dermatol Surg 2018; 44:177.</a></li><li><a class="nounderline abstract_t">Piepkorn MW, Longton GM, Reisch LM, et al. Assessment of Second-Opinion Strategies for Diagnoses of Cutaneous Melanocytic Lesions. JAMA Netw Open 2019; 2:e1912597.</a></li><li><a class="nounderline abstract_t">Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005; 331:481.</a></li><li><a class="nounderline abstract_t">Weinstock MA, Lott JP, Wang Q, et al. Skin biopsy utilization and melanoma incidence among Medicare beneficiaries. Br J Dermatol 2017; 176:949.</a></li><li><a class="nounderline abstract_t">Hansen C, Wilkinson D, Hansen M, Argenziano G. How good are skin cancer clinics at melanoma detection? Number needed to treat variability across a national clinic group in Australia. J Am Acad Dermatol 2009; 61:599.</a></li><li><a class="nounderline abstract_t">Wilkinson D, Askew DA, Dixon A. Skin cancer clinics in Australia: workload profile and performance indicators from an analysis of billing data. Med J Aust 2006; 184:162.</a></li><li><a class="nounderline abstract_t">Criscione VD, Weinstock MA. Melanoma thickness trends in the United States, 1988-2006. J Invest Dermatol 2010; 130:793.</a></li><li><a class="nounderline abstract_t">Zaenker P, Lo J, Pearce R, et al. A diagnostic autoantibody signature for primary cutaneous melanoma. Oncotarget 2018; 9:30539.</a></li><li class="breakAll">Skin Cancer Foundation. Early detection: Overview. Available at: https://www.skincancer.org/early-detection/ (Accessed on July 09, 2017).</li><li class="breakAll">American Academy of Dermatology. Detect skin cancer: How to perform a skin self-exam. Available at: https://www.aad.org/public/diseases/skin-cancer/find/check-skin (Accessed on July 09, 2017).</li></ol></div><div id="topicVersionRevision">Topic 4845 Version 63.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25825511" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8053717" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Melanoma risk in individuals with clinically atypical nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29313949" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cancer statistics, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29313949" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cancer statistics, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33406334" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Rapid Rise in Cutaneous Melanoma Diagnoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33325988" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : UV Exposure and the Risk of Cutaneous Melanoma in Skin of Color: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33325988" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : UV Exposure and the Risk of Cutaneous Melanoma in Skin of Color: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33325988" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : UV Exposure and the Risk of Cutaneous Melanoma in Skin of Color: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16429450" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Developing epidemic of melanoma in the Hispanic population of California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17000949" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ethnic differences among patients with cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22801611" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Anatomic distribution of malignant melanoma on the non-Hispanic black patient, 1998-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20737564" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The expanding melanoma burden in California hispanics: Importance of socioeconomic distribution, histologic subtype, and anatomic location.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22801634" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Skin cancer screening among Hispanic adults in the United States: results from the 2010 National Health Interview Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33461732" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Does acral lentiginous melanoma subtype account for differences in patterns of care in Black patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16728488" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Identifying individuals at high risk of melanoma: a practical predictor of absolute risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9451264" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Can primary prevention or selective screening for melanoma be more precisely targeted through general practice? A prospective study to validate a self administered risk score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21605094" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predicting melanoma risk for the Australian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20520559" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Identifying individuals at high risk of melanoma: a simple tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837981" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk factors and individual probabilities of melanoma for whites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837981" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Risk factors and individual probabilities of melanoma for whites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19189909" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37071089" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37071089" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37071089" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231506" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Why the evidence for skin cancer screening is insufficient: lessons from prostate cancer screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231506" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Why the evidence for skin cancer screening is insufficient: lessons from prostate cancer screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231506" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Why the evidence for skin cancer screening is insufficient: lessons from prostate cancer screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19395122" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Incidence and anatomic presentation of cutaneous malignant melanoma in central Canada during a 50-year period: 1956 to 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19543126" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The anatomic distribution of melanoma and relationships with childhood nevus distribution in Colorado.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15347357" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Trends in the presentation of cutaneous malignant melanoma over three decades at King's College Hospital, London.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380661" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Melanoma in middle-aged and older men: a multi-institutional survey study of factors related to tumor thickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25219716" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions: Part I. Epidemiology, high-risk groups, clinical strategies, and diagnostic technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3312689" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3312689" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3312689" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10086457" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Thickness and delay in diagnosis of melanoma: how far can we go?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8790483" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Screening for melanoma and options for its evaluation [see comment].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8069096" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Recent incidence trends imply a nonmetastasizing form of invasive melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22074699" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Systematic skin cancer screening in Northern Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22911184" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Frequency of excisions and yields of malignant skin tumors in a population-based screening intervention of 360,288 whole-body examinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22517033" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26429634" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Skin Cancer Screening in Germany. Documenting Melanoma Incidence and Mortality From 2008 to 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26480048" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26480048" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22881593" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effectiveness of skin cancer screening programmes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26373399" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Melanoma mortality following skin cancer screening in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28353004" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The effectiveness of a population-based skin cancer screening program: evidence from Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26990272" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Skin self-examination and long-term melanoma survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23378235" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231493" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The role of circumstances of diagnosis and access to dermatological care in early diagnosis of cutaneous melanoma: a population-based study in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380662" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Factors associated with physician discovery of early melanoma in middle-aged and older men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10029126" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Is physician detection associated with thinner melanomas?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19609948" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical whole-body skin examination reduces the incidence of thick melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12756097" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687416" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Routine dermatologist-performed full-body skin examination and early melanoma detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19464598" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Melanoma early detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768448" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The impact of physician screening on melanoma detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22179848" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Behavioral determinants of successful early melanoma detection: role of self and physician skin examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19189368" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28241191" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17438181" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist vs a nondermatologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8795541" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Primary care physicians as gatekeepers in managed care. Primary care physicians' and dermatologists' skills at secondary prevention of skin cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24204060" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The influence of dermatologist and primary care physician visits on melanoma outcomes among Medicare beneficiaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11735713" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A comparison of dermatologists' and primary care physicians' accuracy in diagnosing melanoma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19841400" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Rates of skin cancer screening and prevention counseling by US medical residents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27458944" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Visual Inspection and the US Preventive Services Task Force Recommendation on Skin Cancer Screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24204061" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effects on skills and practice from a web-based skin cancer course for primary care providers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22834687" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The role of general practitioners in diagnosis of cutaneous melanoma: a population-based study in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23937244" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy of a general practitioner training campaign for early detection of melanoma in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16808765" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Diagnosing and managing cutaneous pigmented lesions: primary care physicians versus dermatologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16808765" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Diagnosing and managing cutaneous pigmented lesions: primary care physicians versus dermatologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22614576" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Developing an interactive web-based learning program on skin cancer: the learning experiences of clinical educators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27391802" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Downstream consequences of melanoma screening in a community practice setting: First results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19861521" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Efficacy of skin self-examination practices for early melanoma detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24749902" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Demographic, behavioural and physician-related determinants of early melanoma detection in a low-incidence population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8847720" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Screening for cutaneous melanoma by skin self-examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068264" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26466155" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Total-Body Examination vs Lesion-Directed Skin Cancer Screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286465" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Prevalence of whole-body skin self-examination in a population at high risk for skin cancer (Australia).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20978504" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Skin cancer screening behaviours among individuals with a strong family history of malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22911048" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Improvement in Patient Performance of Skin Self-examinations After Intervention With Interactive Education and Telecommunication Reminders: A Randomized Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27367303" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Early Detection of New Melanomas by Patients With Melanoma and Their Partners Using a Structured Skin Self-examination Skills Training Intervention: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17533068" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Melanoma early detection with thorough skin self-examination: the "Check It Out" randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15520039" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Acceptability and feasibility of a community-based screening programme for melanoma in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11943795" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A randomised trial of population screening for melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16152577" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Increase in skin cancer screening during a community-based randomized intervention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16384764" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Clinical outcomes from skin screening clinics within a community-based melanoma screening program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28659278" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28593242" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Primary Care-Based Skin Cancer Screening in a Veterans Affairs Health Care System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28768305" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Patient Perceptions of Primary Care-Based Skin Cancer Screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30183068" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Psychosocial impact of skin biopsies in the setting of melanoma screening: a cross-sectional survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29094145" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Population-Based Analysis of Histologically Confirmed Melanocytic Proliferations Using Natural Language Processing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22153791" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Increased diagnosis of thin superficial spreading melanomas: A 20-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21244462" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The melanoma 'epidemic', a dermatopathologist's perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30556054" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Concordance and Reproducibility of Melanoma Staging According to the 7th vs 8th Edition of the AJCC Cancer Staging Manual.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32935869" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Terminology for melanocytic skin lesions and the MPATH-Dx classification schema: A survey of dermatopathologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36630138" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29524584" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pathologist characteristics associated with accuracy and reproducibility of melanocytic skin lesion interpretation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28858936" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pathologists' Use of Second Opinions in Interpretation of Melanocytic Cutaneous Lesions: Policies, Practices, and Perceptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31603483" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Assessment of Second-Opinion Strategies for Diagnoses of Cutaneous Melanocytic Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16081427" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Skin biopsy rates and incidence of melanoma: population based ecological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27639256" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Skin biopsy utilization and melanoma incidence among Medicare beneficiaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19664848" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : How good are skin cancer clinics at melanoma detection? Number needed to treat variability across a national clinic group in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16489899" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Skin cancer clinics in Australia: workload profile and performance indicators from an analysis of billing data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19829301" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Melanoma thickness trends in the United States, 1988-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30093967" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A diagnostic autoantibody signature for primary cutaneous melanoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
